(Q43058277)

13 November 2017

1 reference

title

Chemotherapy-induced peripheral neuropathy: an unresolved issue (English)

1 reference

13 November 2017

1 reference

peripheral neuropathy

1 reference

Chemotherapy-induced peripheral neuropathy

inferred from title

1 reference

2

1 reference

13 November 2017

Velasco R

1

1 reference

13 November 2017

language of work or name

Spanish

0 references

publication date

1 March 2010

1 reference

13 November 2017

1 reference

13 November 2017

volume

25

1 reference

13 November 2017

issue

2

1 reference

13 November 2017

page(s)

116-131

1 reference

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature

13 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Peripheral nerve damage associated with administration of taxanes in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

A review on oxaliplatin-induced peripheral nerve damage.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Chemotherapy-induced peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Update on medication-induced peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Chemotherapy-induced neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Cisplatin-lnduced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

The troublesome toxicity of peripheral neuropathy with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Grading of chemotherapy-induced peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Chemotherapy-associated neurotoxicity: an important side effect-impacting on quality, rather than quantity, of life.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted?

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Chemotherapy-induced neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

The role of growth factors in the prevention and treatment of chemotherapy-induced peripheral neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Weekly paclitaxel in the adjuvant treatment of breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Peripheral neurotoxicity of taxol in patients previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Systemic therapy for metastatic colorectal cancer: current options, current evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Clinical management of oxaliplatin-associated neurotoxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Toxicity of platinum compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Oxaliplatin in the treatment of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Thalidomide in the treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Neuropathy in multiple myeloma treated with thalidomide: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Chemotherapy-induced peripheral neurotoxicity: how can we improve knowledge?

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

1 reference

7 January 2021

Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Role of MAPKs in platinum-induced neuronal apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Calpain inhibition protects against Taxol-induced sensory neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Pathogenesis of axonal degeneration: parallels between Wallerian degeneration and vincristine neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by cisplatin: behavioral, structural and biochemical analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Free radicals and antioxidants in chemotherapy-induced toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Therapy of chemotherapy-induced peripheral neuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Chemotherapy-induced peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere).

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Exacerbation of oxaliplatin neurosensory toxicity following surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Neurotoxicity of taxanes: symptoms and quality of life assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Long-term effects of vincristine on the peripheral nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Thalidomide and sensory neurotoxicity: a neurophysiological study

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Impairment of heart rate variability during paclitaxel therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

A practical update on the use of bortezomib in the management of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Toxic neuropathy in patients with pre-existing neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Neurological complications of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Acute vincristine neurotoxicity in the presence of hereditary motor and sensory neuropathy type I.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Charcot-Marie-Tooth disease and vincristine

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Are platinum-based chemotherapeutic drugs safe for patients with Charcot-Marie-Tooth disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

The administration of chemotherapy in a patient with Charcot-Marie-Tooth and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Hereditary neuropathy with liability to pressure palsies emerging during vincristine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Recent advances in drug-induced neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Individualized pharmacotherapy with paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Platinum neurotoxicity pharmacogenetics

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

The usefulness of nerve conduction studies in objectively assessing oxaliplatin-induced peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Total neuropathy score: validation and reliability study

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

CI-PERINOMS: chemotherapy-induced peripheral neuropathy outcome measures study.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Background noise: the experience of chemotherapy-induced peripheral neuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Oxaliplatin-induced neurotoxicity and the development of neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Nerve growth factor prevents experimental cisplatin neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

In vitro protection from cisplatin-induced neurotoxicity by amifostine and its metabolite WR1065.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Limited Access Trial Using Amifostine for Protection Against Cisplatin- and Three-Hour Paclitaxel–Induced Neurotoxicity: A Phase II Study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Measurement of glutathione oxidation and 8-hydroxy-2'-deoxyguanosine accumulation in the gerbil hippocampus following global ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Interventions for preventing neuropathy caused by cisplatin and related compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Vitamin e for the prevention of chemotherapy-induced peripheral neuropathy: rationale for an ongoing clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Acute oxaliplatin-induced peripheral nerve hyperexcitability

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

Efficacy of pregabalin in neuropathic pain in paediatric oncological patients

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol

1 reference

https://api.crossref.org/works/10.1016%2FS0213-4853%2810%2970036-0

7 January 2021

10.1016/S0213-4853(10)70036-0

Identifiers

DOI

1 reference

13 November 2017

1 reference